LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Roche Holding AG is weighing direct-to-patient drug sales in the United States, bypassing the middleman for its pricey medicines for multiple sclerosis, eye disease and cancer. The Swiss drugmaker has ...

Johnson & Johnson’s JNJ Innovative Medicine segment markets several multi-million-dollar drugs that cover a broad range of ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Swiss drugmaker Roche reported better than expected first-half operating profit on Thursday, driven by strong sales of breast ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...